Abstract In April 2008, a nucleotide-sequence-based, complete genome classification system was developed for group A rotaviruses (RVs). This system assigns a specific genotype to each of the 11 genome segments of a particular RV strain according to established nucleotide percent cutoff values. Using this approach, the genome of individual RV strains are given the complete descriptor of Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx. The Rotavirus Classification Working Group (RCWG) was formed by scientists in the field to maintain, evaluate and develop the RV genotype classification system, in particular to aid in the designation of new genotypes. Since its conception, the group has ratified 51 new genotypes: as of April 2011, new genotypes for VP7 (G20-G27), 
Introduction
Rotaviruses (RVs) are members of the family Reoviridae and cause severe diarrheal illness in the young of various animal species [25] . In humans, RV infections lead to the death of more than 500,000 infants and young children each year, particularly in developing regions of the world [72] . RVs possess a genome consisting of 11 segments of double-stranded (ds) RNA [25] . Most segments encode a single polypeptide, allowing the virus to express six structural viral proteins (VPs) and five non-structural proteins (NSPs) [25] . However, in some group A RV strains, a second open reading frame (ORF) is detected in genome segment 11, leading to the expression of another protein product (NSP6) [35] in addition to NSP5. The viral particle has icosahedral symmetry and is composed of three concentric protein layers [25, 65] . VP7 and VP4 are the components of the outermost protein layer (outer capsid), and each carries neutralizing epitopes [25] . The middle protein layer (inner capsid) is composed of VP6 and surrounds the inner layer (the core shell), which is composed of VP2 [65] . Packaged within the core shell are the viral RNA-dependent RNA polymerase (VP1) and RNA capping enzyme (VP3), as well as the 11 dsRNA genome segments [25] . The RV NSPs have various functions in the replication and morphogenesis of RV progeny and in evasion of the host immune response [25] . Based on the antigenic properties of VP6, RVs have been subdivided into five serological species (A-E) and two additional tentative species (F and G) according to the International Committee on Taxonomy of Viruses (ICTV) [4, 79] . These ''RV species'' are commonly referred to as ''RV groups''. RVs belonging to species A, B and C (RVA, RVB and RVC, respectively) are known to infect humans and various animals, whereas RVs of species D, E, F and G (RVD, RVE, RVF and RVG, respectively) thus far have only been recovered from animals, mostly birds [4, 61] . Epidemiologically, RVA is the most important for human infection and disease and has been classified further using various approaches. Specifically, RVA strains have been categorized based on (i) the antigenic properties of VP6, VP7 and VP4 (subgroups, G-serotypes and P-serotypes, respectively); (ii) the migration pattern of the RNA genome segments when subjected to polyacrylamide gel electrophoresis (long, short, supershort or atypical electropherotypes); (iii) whole-genome RNA hybridization patterns (genogroups); and (iv) nucleotide sequence analysis (genotypes) [25, 57] . Due to the segmented nature of the RV genome, reassortment events can occur after coinfection with RV strains belonging to the same group/ species both in vitro and in vivo [27, 34, 64] . Numerous examples of such gene exchanges are available in the literature for RVA strains [50, 61] . Recent data also suggest that reassortment involving the NSP1-encoding genome segment may have occurred between ancestral strains of avian RVA and RVD [92] . However, there is no evidence for reassortment among contemporary RVs that belong to different groups/species. Their inability to undergo segment exchange, even under experimental conditions, indicates that the RV groups can be thought of as unique viral species [4] .
In April 2008, a nucleotide-sequence-based, complete genome classification system was developed for RVA strains [54] . This system assigns a specific genotype to each of the 11 RV genome segments according to established nucleotide percent cutoff values. The VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-NSP4-NSP5/6 genes of RV strains are described using the abbreviations Gx-P[x]-IxRx-Cx-Mx-Ax-Nx-Tx-Ex-Hx (x = Arabic numbers starting from 1), respectively [54] . Full-genome analyses have increased our recognition of the relatedness between animal and human RV strains, and this highlights the relevance of a common nomenclature for both animal and public health. To maintain, evaluate, and develop this system, the Rotavirus Classification Working Group (RCWG) was formed [55] , which includes researchers worldwide.
In this article, we report on the current status of genotype diversity for RVA strains that has been identified to date by the RCWG. Moreover, the RCWG is also working with researchers at the National Center for Biotechnology Information (NCBI) to develop a specific database for the deposition of RV sequence information. This RV resource will contain complete genome sequences that are annotated using VIGOR (VIral Genome ORF Reader) [99] , as well as multiple types of metadata (epidemiological, clinical, etc.) to provide useful additional information to investigators. The new RV database will be very similar to the ''Influenza Virus Resource'', which is widely used to monitor influenza virus strains [10] . As part of the database development, the RCWG herein proposes a standardized nomenclature for RV strains, which is similar to that already established for influenza viruses. Universal adoption of this new system by the RV community will be crucial for the retrieval of relevant information from the RV resource.
Update from the RCWG
The task of the RCWG is to maintain, evaluate, and develop the RV genotype classification system. When the nucleotide sequence from a RVA strain of a potential new genotype is submitted to the RCWG, a thorough phylogenetic analysis is performed, and this analysis is reviewed by the members of the RCWG. When a consensus is reached, the submitter receives an e-mail with the novel genotype number(s) of the particular gene(s), which can then be used in publications. To facilitate the utilization of the RV genotype classification system, a regularly updated online automatic web application, RotaC (http://rotac.regatools.be/), was developed [47] .
Since the establishment of the RCWG, its activities have been reviewed at annual face-to-face meetings, held in conjunction with major scientific virology meetings. The first three RCWG-meetings were held at (i) the 27th annual meeting of the American Society for Virology (ASV) (July 14th, 2008, Ithaca, New York), (ii) the 10th International Symposium on dsRNA Viruses (July 24th, 2009, Hamilton Island, Australia) and (iii) the 29th annual meeting of the ASV (July 19th, 2010, Bozeman, Montana). The fourth and fifth RCWG meetings are planned to take place during the 30th annual meeting of the ASV in Minneapolis, Minnesota (July 16th-20th, 2011) and the 11th International Symposium on dsRNA Viruses in San Juan, Puerto Rico (November 27th-December 1st, 2012), respectively. Table 1 contains a list of RV strains possessing new genotypes that have been recognised by the RCWG since the introduction of the classification system in April 2008. The new genotypes were found for RVs identified in a variety of host species including humans, cows, pigs, horses, mice, chickens, turkeys, pheasants, South American camelids, bats and a sugar glider. Several of these new genotypes have been published [1, 19, 23, 30, 44, 58, 62, 85, 87, 91, 95] . Table 2 shows a large selection of RV strains of all recognised genotypes that are not represented in Table 1 . Table 3 contains a list with representative RV strains and accession numbers for each of the 166 currently established genotypes divided over the 11 genome segments.
Although the RV classification system has so far been limited to that of RVA strains, the RCWG plans to develop similar systems for RV strains belonging to other RV groups/species once a critical number of complete genome sequences has become available. The complete genomes of four human RVB strains were recently sequenced and analyzed by Yamamoto and colleagues, bringing the total number of genomes to eight (seven human RVB strains and a single murine RVB strain) [70, 103] . So far, all of the fully analyzed human RVB strains were detected in China and South-East Asia (Bangladesh, India and Myanmar). Regarding RVC strains, the entire genome sequences have been determined for only eight strains: the porcine strain Cowden and seven human strains detected in the UK, Japan, China, Bangladesh and India [12, 15, 104] [40] . In the future, analysis of these sequence data should allow the calculation of sequence-based thresholds to define (new) RV groups/species and genotypes within groups/species. A detailed overview of the current classification for non-RVA strains was published recently [61] .
Proposed nomenclature of RV strains
Currently, no guidelines exist for the naming of RV strains. The lack of a standardized nomenclature system has lead to discrepancies in the literature where researchers have developed their own naming systems. With increasing numbers of complete RV genome sequences becoming available, and with the development of specific resources to retrieve and analyze these sequences, a more uniform nomenclature is clearly needed. The RCWG has discussed this issue, and we propose the following nomenclature for individual strains: RV group/species of origin/country of identification/ common name/year of identification/G-and P-type A) Guidelines for wild-type RV strains These guidelines apply to any wild-type RV strain or naturally occurring reassortant RV strain recovered from human or animal populations that have been sequenced directly from clinical specimens (such as stool, blood or tissue samples) or environmental samples. Guidelines for nomenclature of i) tissue-culture-adapted RV strains, ii) RV vaccine strains, iii) RV strains that have been generated in the laboratory by reassortment or iv) RV strains engineered in the laboratory by reverse genetics or equivalent mechanisms are provided further below in sections B), C), D), and E). An open space means the genotype is not known because sequencing has not been performed An ''X'' in the name of a strain indicates that this information is missing NP not published a Partial sequences of this gene segment have been determined, but it could not be assigned to any of the established genotypes. It may be the representatives of a new genotype, but the entire ORF needs to be determined, as stated in the guidelines from the RCWG [55] , before this can be confirmed Table 2 List of RV strains representing all of the currently established genotypes except for those represented in Table 1 Strain Proposed rotavirus strain nomenclature 1401 • RV group/species: RVA, RVB, RVC, RVD, RVE, RVF or RVG. RVX should be used in cases where a strain has not yet been assigned to an established or new RV group/species. • Species of origin: The ''species of origin'' field contains two components. The first component is human, pig, cow, dog, cat, rhesus, simian, horse, rabbit, mouse, goat, sheep, guanaco, bat, turkey, chicken, pheasant, sugar glider or other, as appropriate. In cases in which the sample was obtained from the environment (i.e., sewage, soil, river, lake, ocean or similar), ''Env'' should be used. If the species of origin is unknown, ''X'' should be used. The second component is ''-wt'' (for wild-type) to distinguish from tissue-cultureadapted (-tc) and laboratory-generated or -engineered (-lab) RV strains. If a tissue-culture-adapted or laboratory-generated strain is introduced into the population (e.g., a vaccine strain) and later recovered from a human or animal, the species from which the sample was recovered should be used, followed by ''-wt''. The researcher should be able to give a name to a strain without the need to perform any analyses. If subsequent analyses reveal that a strain is wholly or partially derived from a vaccine strain, this information can be added in the metadata of the record in GenBank or any other database.
• Country of identification: A unique 3-letter abbreviation code is used for each country as listed on the website https://www.cia.gov/library/publications/the-worldfactbook/appendix/appendix-d.html. If the country of identification is unknown, ''XXX'' should be used. If a tissue-culture-adapted or laboratory-generated RV strain is introduced into the population and later recovered from a human or animal, the country from which the sample was recovered should be used (further details, e.g., of city/site of identification, can be added in the common name or the metadata; see below).
• Common name: This is a short name given by investigators, preferentially not using forward slashes (''/'') or backslashes (''\'') to avoid confusion and computer-processing problems. If appropriate, the common name can contain geographically/clinically An open space means the (1) genotype not known because sequencing has not been performed or (2) genotypes have not yet been established for non-group-A RVs. An ''X'' in the name of a strain indicates that this information is missing. Accession numbers for representative strains of all the different genotypes can be found in Table 3 NP not published a Only the partial VP8* coding region of the VP4 sequence of P [22] strains is currently available b Genotypes are provisional. Guidelines about the classification of RV strains belonging to RVB and RVC will be determined in the near future by the RCWG c Due to a typographic error, the NSP3 genotype of strain NIC522 was previously misidentified as T2 [5] important information or specific (engineered) mutations, as long as the number of characters is less than or equal to 15.
• Year of identification: This is given using the ''yyyy'' format. If the year of identification is unknown, ''XXXX'' should be used. If a tissue-culture-adapted or laboratory-generated strain is introduced into a population and later recovered from a human or animal, the year in which the sample was recovered should be used.
• G-type: This is given using the form Gx, where x is the established G genotype/serotype number. If the G-type is unknown, GX should be used. Examples of strain names using this nomenclature system can be found in Tables 1 and 2. B) Guidelines for tissue culture-adapted RV strains or RV strain passaged in vivo in their homologous host species
These guidelines apply to any non-vaccine RV strain that has been adapted in tissue culture or passaged in vivo in a homologous animal model without the intention to introduce specific changes in the genome sequence.
Specific details about the number of passages and the cell lines or animal used should be provided in the metadata. Guidelines for nomenclature of i) RV vaccine strains, ii) RV strains that have been generated in the laboratory by reassortment and iii) RV strains engineered in the laboratory by reverse genetics or equivalent mechanisms are provided below in sections C), D) and E).
• RV group/species: See section A) above.
• Species of origin: The ''species of origin'' field contains two components. The first component is human, pig, cow, dog, cat, rhesus, simian, horse, rabbit, mouse, goat, sheep, bat, guanaco, turkey, chicken, pheasant, sugar glider or other, as appropriate. If the sample was obtained from the environment (i.e., sewage, soil, river, lake, ocean or similar), ''Env'' should be used. If the species of origin is unknown, ''X'' should be used. The second component is ''-tc'' (for tissue cultured) or ''-hhp'' (homologous host passaged) to distinguish from wild-type (-wt) and laboratory-generated or engineered (-lab) RV strains. If a tissue-culture-adapted or in vivopassaged RV strain is introduced into the population (e.g., a vaccine strain) and later recovered from a human or animal, the species from which the sample was recovered should be used followed by ''-wt''. • Country of identification: A unique 3-letter abbreviation code is used for each country as listed on the website https://www.cia.gov/library/publications/ the-world-factbook/appendix/appendix-d.html. If the country of identification is unknown, ''XXX'' should be used. If a tissue-culture-adapted RV strain is introduced into the population and later recovered from a human or animal, the country from which the sample was recovered should be used (further details, e.g., of city/ site of identification, can be added to the common name or the metadata, see below).
• Common name: See section A) above • Year of identification: This is given using the ''yyyy'' format. If the year of identification is unknown, ''XXXX'' should be used. If a tissue-cultured strain is introduced into a population and later recovered from a human or animal, the year in which the sample was recovered should be used.
• G-type: See section A) above.
• P-type: See section A) above.
Examples of strain names using this nomenclature system can be found in Tables 1 and 2. C) Guidelines for RV strains generated in a laboratory for which a host species can be assigned unambiguously
These guidelines apply to any RV strain in which small deliberate changes have been introduced (examples: chemically mutagenised RV strains, moderately modified RV strains using reverse genetics techniques, etc.) or RV strains that were passaged in a heterologous animal model and for which there is no ambiguity about the original host species. Specific details about the introduced changes and the methods used should be provided in the metadata. Guidelines for nomenclature for i) RV vaccine strains, ii) RV strains that have been generated in the laboratory by reassortment, iii) RV strains with a designed synthetic sequence generated using reverse genetics or iv) RV strains in which large modifications have been applied using reverse genetics or equivalent mechanisms are provided below in sections D) and E).
• Species of origin: The ''species of origin'' field contains two components. The first component is human, pig, cow, dog, cat, rhesus, simian, horse, rabbit, mouse, goat, sheep, bat, guanaco, turkey, chicken, pheasant, sugar glider or other, as appropriate. If the sample was obtained from the environment (i.e., sewage, soil, river, lake, ocean or similar), ''Env'' should be used. If the species of origin is unknown, ''X'' should be used. The second component is ''-lab'' (lab engineered) to distinguish from wild-type (-wt) and tissue-culture (-tc)-adapted RV strains. If a laboratory-generated strain is introduced into the population (e.g., a vaccine strain) and later recovered from a human or animal, the species from which the sample was recovered should be used followed by ''-wt''.
• Country of identification: A unique 3-letter abbreviation code is used for each country as listed on the website https://www.cia.gov/library/publications/ the-world-factbook/appendix/appendix-d.html. If the country of identification is unknown, ''XXX'' should be used. If a laboratory-generated strain is introduced into the population and later recovered from a human or animal, the country from which the sample was recovered should be used (further details, e.g., of city/ site of identification, can be added to the common name or the metadata, see below).
• Common name: See section A) above.
• Year of identification: This is given using the ''yyyy'' format. If the year of identification is unknown, ''XXXX'' should be used. If a laboratory-engineered strain is introduced into a population and later recovered from a human or animal, the year in which the sample was recovered should be used.
Examples of strain names using this nomenclature system can be found in Table 2 . D) Guidelines for RV strains generated in a laboratory for which a host species cannot be assigned unambiguously
These guidelines for nomenclature apply to RV strains that have been generated in the laboratory by reassortment (except for vaccine strains), strains with a designed synthetic sequence generated using reverse genetics, strains in which large modifications have been applied using reverse genetics or RV strains generated by combinations of the above procedures. Specific details about the changes introduced and the methods used should be provided in the metadata.
• Species of origin: ''LabStr''. More specific details about the procedure used to create the virus should be provided in the metadata.
• Country of identification: The country in which the RV strain was generated should be provided according to the unique 3-letter abbreviation code for each country: https://www.cia.gov/library/publications/the-worldfactbook/appendix/appendix-d.html.
• Common name: This is a short name given by investigators, preferentially without the use of forward slashes (''/'') or backslashes (''\'') to avoid confusion. If appropriate, the common name can contain specific information about the laboratory strain, such as the procedure used to generate it, as long as the number of characters is less than or equal to 15.
• Year of identification: The year in which the RV strain was generated should be provided using the ''yyyy'' format.
Examples using this nomenclature system for naming laboratory strains can be found in Table 4 .
E) Guidelines for RV vaccine strains
Due to the increasing use of live-attenuated RV vaccine, it will be important to distinguish vaccine strains from naturally-occurring wild-type strains. Therefore, a specific notation for vaccine strains was developed and should be used if the strain is the sole component or part of a multicomponent live vaccine. Only the sequences obtained from virus production lots or batches are officially recognized as vaccine strains and should have ''vaccine'' in their strain name. Other ''pre-vaccine'' strains or sequences of strains that were used in laboratories and were not generated by sequencing the actual vaccine production lots of a given manufacturer should use the normal guidelines to name their strains. Additional information such as the ''prevaccine'' status of a strain could be added in the ''common name'' section or in the metadata of the record.
• Species of origin: ''Vaccine''. Further specific details about the generation of the vaccine strain should be provided in the metadata.
• Country of identification: The country in which the vaccine strain was recovered (in the case of a vaccine containing a tissue-culture-adapted strain) or developed (in the case of a vaccine developed using reassortment or in vitro engineering) should be provided according to An open space means that the genotype has not been established/determined a Hypothetical name of an RV strain identified in a river in Switzerland [3] b Strain SA11-tsE is a temperature-sensitive RV strain (SA11) generated using chemical mutagenesis [78] c Strain PP-1 is a bovine RV strain that has been passaged several times in the heterologous pig model [22] d Hypothetical name of a RV strain generated using in vitro reassortment in cell culture, possessing an RRV-like gene background with the VP4 gene (genotype P [20] ) of the murine RV strain EHP [46] e Hypothetical name of a RV strain generated using reverse genetic techniques, possessing an SA11-like gene background with the NSP2 gene (genotype N2) of the human RV strain DS-1 [90] f Hypothetical names of the 5 reassortant RV strains present in the RotaTeq vaccine [60] g Hypothetical name of the RV strain present in the Rotarix vaccine Proposed rotavirus strain nomenclature 1407 the unique 3-letter abbreviation code for each country: https://www.cia.gov/library/publications/the-worldfactbook/appendix/appendix-d.html.
• Common name: This is a short name given by investigators, preferentially without the use of forward slashes (''/'') or backslashes (''\'') to avoid confusion. It is recommended that the commercial name of the vaccine is included in the common name. The number of characters should be less than or equal to 15.
• Year of identification: The year in which the RV strain was recovered (in the case of a vaccine containing a tissue-culture-adapted strain) or developed (in the case of a vaccine developed using reassortment or in vitro engineering) should be provided using the ''yyyy'' format.
Examples using this nomenclature system for naming vaccine strains can be found in Table 4 .
RV resource under development at NCBI
Due to the rapid increase in the number of complete RV genome sequences available, the RCWG is working with NCBI to develop an advanced RV resource, which will include a value-added database and a suite of tools for the analysis of RV sequences. When new sequence records are submitted to GenBank, their contents will be added to the RV database through an automated process. A web-based interface will allow researchers to search the RV database using a variety of genetic, epidemiological and clinical criteria, retrieve relevant sequences and analyze them. With this in mind, the RCWG proposes that the following list of biological descriptors (if available and relevant) should be included with sequence records submitted to GenBank. This list of metadata was agreed upon by members of the RCWG but is by no means exclusive, as additional metadata can also be added.
Strain-specific features
• a) Wild-type primary strain b) Cell-culture-adapted strain c) In vitro-generated reassortant strain d) Strain engineered by reverse genetics procedures e) In vitro-generated reassortant RV strain or RV strain engineered by reverse genetics that was recovered in nature from any host (e.g., a vaccine strain recovered in a human infant) f) In vivo-generated strain resulting from reassortment of a laboratory-generated strain and a wild-type strain (e.g., a strain recovered from a vaccinated infant that is the result of a reassortment event of the vaccine stain and a wild-type strain).
• 
Conclusions
The quickly evolving sequencing capabilities of research laboratories and commercial organizations around the world have resulted in a rapid growth of sequence data for RVs, and dealing with these data has become a major challenge. In an attempt to introduce a systematic method of naming RV strains, the RCWG proposes the following nomenclature: RV group/species of origin/country of identification/common name/year of identification/G-and P-type. In this nomenclature, specific guidelines were developed for wild-type RV strains, tissue-culture-adapted strains, RV vaccine strains and RV strains that have been generated or engineered in a laboratory using reassortment or reverse genetics procedures. The current proposal only leaves room for 15 explanatory characters in the ''common name'' section of the complete strain name. For all of the other sections (RV group, species of isolation, country of isolation, year of isolation and G/P-genotype), the guidelines are very rigorous. The reason for allowing the freedom of choosing 15 characters in the ''common name'' section is to provide authors an opportunity to highlight specific or important information. Examples of information that could be added include: i) the city or state of strain identification, ii) clinical outcomes or viral phenotypic characteristics and iii) mutations or engineered changes in the viral genome. However, we think that it is impossible to include all relevant information about a strain in the actual name. Instead, such information should be added in the metadata linked to each record in GenBank or any other database. The RCWG is fully aware that it is impossible to define rules for each real-life or hypothetical situation, especially when a strain has undergone several types of manipulations (e.g., a combination of cell culture adaptation, passaging in a homologous host animal and the introduction of reversegenetic engineered mutations). Therefore, we encourage researchers to choose a strain name that appears to be most appropriate or to contact the RCWG for guidance. While it is not necessary to include in the actual strain name, detailed information about manipulations should be added to the metadata of a record.
This standardized naming procedure is reminiscent of the nomenclature guidelines for influenza viruses and will be very useful for future analysis. However, this system will only succeed if the entire research community supports and adheres to the proposed guidelines. Regarding the use of this new nomenclature in scientific articles, the RCWG suggests that authors use the full strain name the first time it is mentioned in the text and then subsequently use the ''common name'' (i.e., a suitable abbreviation). In addition, authors should consider using the full strain name in phylogenetic trees, tables and figures if it enhances the interpretation or presentation of the data. However, depending on the individual characteristics of a manuscript, authors have the flexibility to use alternative strategies.
Towards utilizing the large amount of RV nucleotide sequence data, an RV-specific database is being developed by the NCBI, which is expected to be launched in the second half of 2011. This resource will be similar to the NCBI Virus Variation resources developed for influenza and dengue viruses [10, 81] and the resources developed at the Los Alamos National Laboratory for hepatitis C virus (HCV) [43] and for human immunodeficiency virus (HIV) (http://www.hiv.lanl.gov./content/). RV nucleotide sequence data, as well as metadata describing the biological and epidemiological context of associated sequences, will be stored in specially designed relational databases. A new, user-friendly web interface will allow investigators to construct and explore resource queries based on a variety of criteria. Additionally, novel web-based tools and displays will allow users to compare retrieved nucleotide and protein sequences on the basis of chronology, geography and biological significance. In order to fully exploit the possibilities of such a resource for the study of viral epidemiology, seasonality, geographical spread, links between specific strains and clinical manifestations, possible vaccine escape-mutants, etc., it is imperative that nucleotide sequence submissions include relevant metadata. In addition, the RCWG strongly encourages researchers to retrospectively update the names of their RV sequences in GenBank and add relevant metadata to the files. This process is straightforward and will greatly enhance the scientific potential of individual sequence records. From Table 1 , it is obvious that close monitoring, updating and genotype assignment activities of the RCWG as practiced during the past three years are absolutely necessary to sustain and develop the new RV genotype-based classification and nomenclature system. With the increasing number of sequence data becoming available for non-RVA strains, the activities of the RCWG will probably be expanded in the near future.
